SGMO vs. HRTX

In the year-to-date period, SGMO achieves a 7.84% return, which is significantly lower than HRTX's 10.46% return. Over the past 10 years, SGMO has underperformed HRTX with an annualized return of -23.98%, while HRTX has yielded a comparatively higher -17.17% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Sangamo Therapeutics, Inc. (SGMO) and Heron Therapeutics, Inc. (HRTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current SGMO Sharpe Ratio is 0.03, which is higher than the HRTX Sharpe Ratio of -0.46. The chart below compares the historical Sharpe Ratios of SGMO and HRTX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither SGMO nor HRTX has paid dividends to shareholders.

The maximum SGMO drawdown since its inception was -99.40%, roughly equal to the maximum HRTX drawdown of -99.96%. Use the drawdown chart below to compare losses from any high point for SGMO and HRTX. For additional features, visit the drawdowns tool.

Sangamo Therapeutics, Inc. (SGMO) and Heron Therapeutics, Inc. (HRTX) have volatilities of 18.12% and 18.12%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Sangamo Therapeutics, Inc. and Heron Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.